Douglas Dong Fang

This inventor holds 14 USPTO granted patents and 18 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited, Ascentage Pharma (Suzhou) Co., Ltd.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Douglas Dong Fang. Retrieved from https://idiyas.com/inventor/douglas-dong-fang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 18)

% Patents Active = 92.9

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

13 out of 31

Ascentage Pharma (Suzhou) Co., Ltd.

patents

8 out of 29

Ascentage Pharma Group Corp Limited

patents

1 out of 10

Ascentage Pharma (Suzhou) Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2022-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12728113 - Microsuspension of an MDM2 inhibitor and therapeutic applications thereof (2026-09-08),

2. 12514863 - Pharmaceutical combination and use thereof (2026-01-06),

3. 12370197 - Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases (2025-07-29),

4. 12287338 - Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway (2025-04-29),

5. 12268665 - Combination of immunotherapies with MDM2 inhibitors (2025-04-08),

6. 12233047 - Pharmaceutical combination and use thereof (2025-02-25),

7. 12194024 - Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease (2025-01-14),

8. 12186304 - Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule (2025-01-07),

9. 12083136 - Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof (2024-09-10),

10. 11478477 - Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor (2022-10-25),

11. 11478470 - Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases (2022-10-25),

12. 11478469 - Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases (2022-10-25),

13. 11452716 - Pharmaceutical composition and use thereof (2022-09-27),

14. 11395815 - Compound for treating osteoarthritis (2022-07-26),

Title: The Career Journey of Douglas Dong Fang

Introduction: Douglas Dong Fang is an inventive mind based in China, contributing to the pharmaceutical sector through his work at Ascentage Pharma Co., Ltd. Despite not holding any patents, he plays a crucial role in research and development within his organization.

Latest Patents: As of now, Douglas Dong Fang does not hold any patents registered in his name, indicating a focus on collaboration and innovation rather than individual recognition.

Career Highlights: Douglas has made significant contributions to Ascentage Pharma, a company known for its focus on innovative therapies for cancer and other serious diseases. Throughout his career, he has been dedicated to advancing pharmaceutical research aimed at improving patient outcomes.

Collaborations: At Ascentage Pharma, Douglas works alongside notable colleagues such as Dajun Yang and Yifan Zhai. These collaborations enrich the innovative environment, fostering a culture of teamwork and shared expertise in the field of pharmaceuticals.

Conclusion: Douglas Dong Fang's journey in the pharmaceutical industry reflects the importance of teamwork and collective innovation. His commitment to research at Ascentage Pharma Co., Ltd. highlights the potential for future breakthroughs, even in the absence of personal patents.

Profile summary based on public USPTO records.